Uterine leiomyosarcoma (UtLMS) is resistant to chemotherapy and radiotherapy; therefore, surgical interventions are virtually the only means of clinical treatment. In UtLMS the 5 year survival rate is approximately 35%. Difficulties are reported in distinguishing UtLMS from other uterine mesenchymal tumors, diagnosis generally requires surgery and cytoscopy; therefore, a diagnostic method needs to be established that can identify nonstandard smooth muscle differentiation. Using molecular analyses, our research group identifies cellular factors, which are established as potential biomarker for UtLMS, specifically enriched in clinical materials derived from Pts with UtLMS. The molecular experiments demonstrated differential expression of cyclin E and P27 via PSMB9 expression. The discovery of differential expression of factors on a key cell signaling pathway may provide new targets for diagnostic approaches and therapeutic intervention. Efficacy and reliability of candidate biomarker as a differential diagnosis for uterine mesenchymal tumor have been examined by clinical study PRUM-IBio study. We will report findings of this study. The study is conducted under ethical guidelines.

Dr. Hayashi is professor at Shinshu University Graduate School of Medicine since 2002, and Section Head at National Hospital Organization Kyoto Medical Center since 2018. He received his Ph.D. from Inst. for Medical Science, University of Tokyo in 1994. He was research training as a resident staff in Virology Division, at National Cancer Center, Tokyo Japan for 3 years until 1994 and joined Whitehead Institute (WI)/Mass.Inst.Tech.(M.I.T.) that year. He did postdoctoral training in the laboratory of Dr. Rick A. Young (Membership in the National Academy of Sciences, WI/M.I.T.), and also was a research member of USA Project of AIDS vaccine development (Project Leader: Dr. David Baltimore, Nobel Laureate, Cal.Tech.). After postdoctoral training, he got faculty position Lecture, Mass. General Hospital (MGH)/Harvard Medical School (HMS) in 1997. He has been studying the antigen presentation system by MHC class I with LMP2-deficient mice, under the cooperation of Dr. Susumu Tonegawa (Nobel Laureate, M.I.T.). He identifies diagnostic biomarkers, LMP2, Cyclin B1 and Cyclin E, for malignant tumor, i.e. uterine leiomyosarcoma, and BRCA1 and S100A4 for ovarian carcinoma. Current research focus: molecular approach of tumorigenesis of uterine leiomyosarcoma and ovarian cancer.